Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF

Like galore maturation stocks, drugmaker Eli Lilly (NYSE: LLY) is down sharply twelvemonth to date. Its 15.6% diminution is weighing connected the healthcare sector, arsenic probe by The Motley Fool shows that Lilly is by acold the astir invaluable U.S. healthcare company.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Below we'll look astatine wherefore it's nether pressure, and see a low-cost exchange-traded money (ETF) that has a important weighting successful Eli Lilly.

Eli Lilly makes galore antithetic medicines to dainty conditions specified arsenic Alzheimer's disease, autoimmune diseases, cancer, diabetes, obesity, tegument conditions, migraines, and slumber apnea. But nary class is driving the banal much than its GLP-1 drugs: Mounjaro (for benignant 2 diabetes) and Zepbound (for value nonaccomplishment management).

In 2025, Mounjaro and Zepbound accounted for a combined 56% of full revenue, compared to 36.7% successful 2024. But concentrated maturation is simply a double-edged sword, arsenic Lilly is present much susceptible to pricing pressure, competition, and decisions by the Food and Drug Administration successful a azygous category.

The banal has tally up a batch successful caller years, with Eli Lilly's marketplace headdress concisely exceeding $1 trillion. Lilly's valuation is heavy babelike connected maintaining its industry-leading presumption successful the weight-loss cause space; it presently has a lofty price-to-earnings (P/E) ratio of 40.1. The guardant P/E, which assumes precocious growth, is much tenable astatine 26.1. But there's nary denying that the company's net are driven by value nonaccomplishment drugs -- which adds risk, but besides imaginable reward.

If request continues, Eli Lilly volition look inexpensive successful hindsight, fixed its breakthrough maturation rate. But there's besides a hazard that net dramatically dilatory oregon adjacent crook antagonistic if there's a cyclical slowdown oregon amended value nonaccomplishment alternate -- which would apt instrumentality a sledgehammer to the banal price.

The Vanguard Healthcare ETF (NYSEMKT: VHT) is arguably a amended bargain than Eli Lilly. It's a bully value. It has diversified vulnerability to a assortment of healthcare stocks, yet inactive holds a sizable 12.6% weighting successful Lilly, its largest holding. The money holds implicit 400 stocks, including biotech and pharmaceutical companies, healthcare instrumentality makers, and security companies.

Owning the full assemblage alternatively than going each successful connected Eli Lilly is simply a catch-all mode to payment from the industrywide roar successful value nonaccomplishment drugs, alternatively than banking connected Lilly protecting its marketplace stock against competitors. The ETF present sports a P/E of 25.3 and a output of 1.6% -- which is simply a somewhat amended worth and provides higher income compared to the Vanguard S&P 500 ETF's 25.8 P/E and 1.1% dividend yield.